louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01873651: Longterm Outcome of the Delta III Inverse Prosthesis
Official title: The Reverse Delta III Total Shoulder Prosthesis - Longerm Results in 98 Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Rotator Cuff Tear Arthropathy
Lead sponsor: Schulthess Klinik
Sponsor class: OTHER
First posted: 2013-06-10
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the study is to describe the results after \> 10 years due to a prosthesis implant.

Detailed description: The aim of the study is to measure the gain of the benefit in function an painreduction which the patient yields with this type of prosthesis in a longterm (\> 10 years )outcome. Additionally the long-term results will be compared with the mid-term results and the literature. Furthermore the complications since the mid-term measurement time point will be determined.

Eligibility criteria: Inclusion Criteria:

* implantation of a Delta III - prothesis
* timeframe (Oct 1998 - Dec 2002)
* delta-pectoral approach
* written informed consent

Exclusion Criteria:

* Implantation because of a revision
* Complaints, which make it difficult to follow instructions or even prevent

Primary outcomes:
measure: Constant Murley Score
timeFrame: 10 years
Secondary outcomes:
measure: cASES
timeFrame: 10 years
measure: pASES
timeFrame: 10 years
measure: SF-36
timeFrame: 10 years
measure: DASH-Questionannaire
timeFrame: 10 years
measure: SPADI
timeFrame: 10 years
measure: x-ray (Sperling Classification)
timeFrame: 10 years
measure: x-ray (Sirveaux Classification)
timeFrame: 10 years
measure: Description of the glenoid
timeFrame: 10 years
measure: Description of the stem
timeFrame: 10 years
Other outcomes:
Locations:
Study officials:
affiliation: Schulthess Klinik, Upper Extremities Department
name: Matthias Flury, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05842551: Prismatic Lenses and tDCS in Neglect
Official title: The Effect of Prismatic Lenses in Association With tDCS in Patients With Neglect: a Pilot Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stroke, Ischemic
Keywords: stroke
neglect
tDCS
prismatic lenses
Lead sponsor: Istituti Clinici Scientifici Maugeri SpA
Sponsor class: OTHER
Collaborators: name: Azienda USL Toscana Sud Est
First posted: 2023-05-06
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to to evaluate the effect and feasibility of a rehabilitation protocol with prismatic lenses associated with tDCS, compared to a prismatic lens rehabilitation protocol associated with sham stimulation, in reducing the signs of neglect in a group of patients with spatial heminegligence following ischemic stroke of the right hemisphere.

The secondary objective is to evaluate the impact of this rehabilitation protocol on functional outcome.


Eligibility criteria: Inclusion Criteria:

* age \>18 years
* ischemic stroke
* hospitalization within 90 days of the event

Exclusion Criteria:

* heamorrhagic stroke
* history of neurological disease
* history of psychiatric disease
* use of alchool and drugs

Primary outcomes:
measure: Neuropsychological outcome
timeFrame: Change from baseline OCS at 2 weeks
measure: Neuropsychological outcome
timeFrame: Change form baseline the semi structured scale for the functional evaluation of extrapersonal neglect at 2 weeks
measure: Neuropsychological outcome
timeFrame: Change form baseline the semi structured scale for the functional evaluation of personal neglect at 2 weeks
measure: Neuropsychological outcome
timeFrame: Change from baseline the Bergegò Scale at 2 weeks.
measure: Functional outcome
timeFrame: Change from baseline the Barthel Index at 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Bari
country: Italy
facility: Istituti Clinici Scientifici Maugeri
state: Ba
Study officials:
affiliation: Istituti Clinici Scientifici Maugeri
name: Simona Spaccavento
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02376751: An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency
Official title: AN EXPANDED ACCESS PROTOCOL FOR SEBELIPASE ALFA FOR PATIENTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Lysosomal Acid Lipase Deficiency
Keywords: Cholesteryl Ester Storage Disease
Acid lipase disease
Cholesterol ester hydrolase deficiency
LIPA Deficiency
Wolman disease
Lysosomal Storage Disease
Lead sponsor: Alexion Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2015-03-03
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: This is an open-label, multicenter expanded access protocol to allow patients with a confirmed diagnosis of Lysosomal Acid Lipase (LAL) Deficiency in the United States (US), access to sebelipase alfa (recombinant lysosomal acid lipase \[rhLAL\]) until commercial product is available.

Patients enrolled in the expanded access protocol will receive 1 mg/kg intravenous infusions of sebelipase alfa every other week.


Eligibility criteria: Inclusion Criteria:

1. Patient is ≥ 8 months of age at commencement of treatment with sebelipase alfa.
2. Patient has a confirmed diagnosis of LAL Deficiency.
3. Patient or patient's parent or legal guardian (if applicable) consents to participation in the study. If the patient is of minor age, he/she is willing to provide assent where required per local regulations, and if deemed able to do so.
4. Male and female patients of childbearing potential must use a highly reliable method of birth control (expected failure rate less than 5% per year) from the time they commence treatment through 4 weeks after the last dose of sebelipase alfa.
5. Women of childbearing potential must have a negative serum pregnancy test at commencement of treatment with sebelipase alfa.

Exclusion Criteria:

1. Women who are nursing or pregnant.
2. Patients who received an investigational product within 30 days (for a small molecule) or 60 days (for a biologic) of commencing treatment, and which in the opinion of the investigator or Sponsor, may negatively impact patient safety.
3. Patients who have received sebelipase alfa as part of a clinical trial that is currently active.
4. Patients with known hypersensitivity to eggs.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04338451: Music During ESWL for Half Treatment
Official title: Music Listening to Decrease Pain and Discomfort During Extracorporeal Shock Wave Lithotripsy (SWL): a Prospective Randomized Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Urolithiasis
Keywords: Urolithiasis
Kidney Calculi
Lithotripsy
Pain Management
Music
Lead sponsor: A.O.U. Città della Salute e della Scienza
Sponsor class: OTHER
First posted: 2020-04-08
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to evaluate if music listening relieves pain and discomfort during Extracorporeal Shock-Waves Lithotripsy (ESWL).

Detailed description: Patients undergoing ESWL and interested in music listening are randomly divided in two groups: patients in group A listen to music during the first part of the treatment (first 1800 SW), patients in group B during the second part.

At the end of the treatment patients are asked to fill in a questionnaire. They are asked if they were pleased to have had the opportunity to listen to music during ESWL, if they would like to listen to music again in case of further treatments, if they consider music helpful in relieving pain and discomfort during ESWL. Patients are also asked to mark their level of pain during each part of the treatment on a visual analogue scale (VAS) for pain.

Eligibility criteria: Inclusion Criteria:

* All patients undergoing ESWL from February 2011 to October 2012 and interested in music listening

Exclusion Criteria:

* Contraindication to ESWL
* No interest in music listening
* \< 18 years and \> 80 years

Primary outcomes:
measure: percentage of patients who appreciated music listening during SWL without anesthesia
timeFrame: 10 mins after SWL treatment completed
Secondary outcomes:
measure: percentage of patients who considered music useful to relieve pain
timeFrame: 10 mins after SWL treatment completed
measure: change in SW voltage (kV)
timeFrame: 10 mins after SWL treatment completed
measure: change in VAS score
timeFrame: 10 mins after SWL treatment completed
measure: change in analgesic request
timeFrame: 10 mins after SWL treatment completed
measure: change in requested interruptions
timeFrame: 10 mins after SWL treatment completed
measure: change on VAS scores separately measured in each part of the treatment
timeFrame: 10 mins after SWL treatment completed
Other outcomes:
Locations:
city: Turin
country: Italy
facility: AOU Città della Salute e della Scienza
Study officials:
affiliation: AOU città dellaSalute e della Scienza, Torino
name: Andrea MD Bosio, MD
role: STUDY_CHAIR
affiliation: AOU città dellaSalute e della Scienza, Torino
name: Andrea MD Bosio, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: AOU città dellaSalute e della Scienza, Torino
name: Andrea MD Bosio, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05188651: Effect of FFP2 Masks on Peripheral Oxygen Saturation and Pulse Rate During the COVID-19 Pandemic
Official title: Effect of FFP2 Masks on Peripheral Oxygen Saturation and Pulse Rate During the COVID-19 Pandemic
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hypoxia
Hypercapnia
COVID-19 Pandemic
Lead sponsor: Catholic University of the Sacred Heart
Sponsor class: OTHER
First posted: 2022-01-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all kind of dental professionals

Brief summary: aim of this research is to evaluate the effects of FFP2/N95 masks on peripheral oxygen saturation and pulse rate in dental professionals


Eligibility criteria: Inclusion Criteria:

* dental professionals

Exclusion Criteria:

* subjects not signing informed consent
* subjects unable to wear facemasks due to underlying conditions

Primary outcomes:
measure: change in peripheral oxygen saturation using FFP2/N95 masks
timeFrame: before wearing face mask, after 30 minutes, after 1 hour, at the end of the clinical activity after 4-5 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Policlinico Universitario A. Gemelli
state: RM
Study officials:
References:
Clinical trial NCT02166151: Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
Official title: Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Chronic Idiopathic Urticaria
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2014-06-18
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.


Eligibility criteria: Inclusion Criteria:

* diagnosis of chronic idiopathic urticaria for 3 months
* failure on treatment with at least 2 antihistamins and systemic corticosteroids or cyclosporin

Exclusion Criteria:

* physical or cholinergic urticaria
* past treatment in Omalizumab i nprevious year
* parasitic infection
* malignancy in last 5 years
* known sensitivity to Omalizumab

Primary outcomes:
measure: Percentage of Participants with ≥ 50% Decrease in Urticaria Activity Score (UAS)
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Petah Tikva
country: Israel
facility: Rabin Medical Center
Study officials:
affiliation: Rabin Medical Center
name: Michael David, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00197951: Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism
Official title: Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology, Not Being a Severe Mental Disorder, Associated to Alcohol Dependence Disorder.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Depression
Anger
Anxiety
Alcoholism
Keywords: Psychiatric symptoms associated to alcoholism recovery
Alcoholism treatment
Alcohol craving
Relapse to heavy drinking
Abuse of other substances during alcoholism recovery
Lead sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2005-09-20
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Alcohol dependent patients show comorbid psychiatric symptoms, related to malfunction of dopamine, norepinephrine and serotonin neurotransmission, during early recovery. Ziprasidone can improve malfunctioning of these disregulated systems, thereby improving anxiety, depression, anhedonia, anger, and alcohol craving.

Detailed description: 60 alcohol-dependent patients will be included, once finished alcohol detoxification treatment.Thirty patients will receive ziprasidone treatment, in progressively increasing doses, starting from 40 mg per day, and the other 30 patients will receive placebo, in a double blind procedure

Eligibility criteria: Inclusion Criteria:

* DSM-IV-TR criteria for alcohol dependence disorder
* Age between 18 -65 years old.
* Score 7 or higher in the GHQ-28 scale.

Exclusion Criteria:

* More than 30 days without drinking alcohol.
* Severe medical disorders.
* Psychotic or bipolar disorders severely decompensated requiring antipsychotic medication.
* Opiate, cocaine or benzodiazepine dependence disorders, requiring more than one week of detoxification treatment.
* Pregnant or lactating women

Primary outcomes:
measure: Score opf SCL-90-R psychiatric symptoms scale.
Secondary outcomes:
measure: Alcohol consumption (amount and frequency)
measure: Alcohol craving
measure: Other substances consumption
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Unidad de Conductas Adictivas//Servicio de Psiquiatría//Hospital de la Santa Creu i Sant Pau
Study officials:
affiliation: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
name: Josep Guardia, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00677651: Sex Differences in Gene Expression in Human Adipose Tissue
Official title: Sex Differences in Gene Expression in Human Adipose Tissue
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Obesity
Keywords: adipose
lean
obese
overweight
healthy
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
Collaborators: name: University of Maryland
First posted: 2008-05-14
Enrollment: 10
Sex: ALL
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: General Population

Brief summary: This project was created to assess sex differences in adipose tissue gene expression in different locations in the body. The primary objectives are to understand:

1. The mechanisms of differential body fat distribution in men and women
2. How body fat distribution is affected by reproductive hormones
3. The mechanisms linking fat distribution to health risks such as diabetes


Eligibility criteria: Inclusion Criteria:

* Caucasian men and women 20-35 years of age
* Lean (BMI less than 25)
* Obese (BMI 30-35)

Exclusion Criteria:

* Hormonal birth control
* Pregnancy
* Smokers
* History of diabetes, kidney, liver or thyroid disease
* History of cancer

Primary outcomes:
measure: Adipose and blood sampling
timeFrame: 1 year
Secondary outcomes:
measure: CT scan and DEXA scan
timeFrame: 1 year
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: UCSD
state: California
Study officials:
affiliation: UCSD
name: Jeffrey Chang, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03388151: Propofol Versus Midazolam for Lower Gastrointestinal Endoscopy
Official title: Effect of Use of Propofol Versus Use of Midazolam as Sedative Agent in Patients With Liver Cirrhosis Presented for Lower Gastrointestinal Endoscopy, Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Cirrhosis, Liver
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2018-01-02
Enrollment: 100
Sex: ALL
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: propofol versus use of midazolam as sedative agent in patients with liver cirrhosis presented for lower gastrointestinal endoscopy

Detailed description: Effect of use of propofol versus use of midazolam as sedative agent in patients with liver cirrhosis presented for lower gastrointestinal endoscopy, Randomised controlled trial.

Eligibility criteria: Inclusion Criteria:

* Liver cirrhosis
* presented to colonoscopy

Exclusion Criteria:

* Encephalopathy
* Hypersensitivity
* Coagulopathy

Primary outcomes:
measure: Number of patients adequately sedated
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Sherief Abd-Elsalam
Study officials:
affiliation: Gastroenterology
name: Sherief Abd-Elsalam, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Tanta University Anasthesia Department
name: Sameh Abdelkhalek Ahmed, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05256251: Westlake Longevity Cohort
Official title: Westlake Longevity Cohort
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Aging
Keywords: Gut microbiome
Aging
Lead sponsor: Westlake University
Sponsor class: OTHER
First posted: 2022-02-25
Enrollment: 1500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All the participants should be Chinese residents, regardless of the ethics.

Brief summary: The Westlake Longevity Cohort (We-Longevity) is a prospective cohort study among centenarians, nonagenarians and senior citizens living in Lishui, China. The primary aim of this cohort is to characterize the multi-omics molecular characteristics of healthy longevity and their dynamic trajectories. The second aim is to culture the gut microbiota of these elderly people through culturomics. The third aim of We-Longevity is to investigate the association of dietary and lifestyle with the multi-omics molecular characteristics of healthy longevity, and to facilitate the development of personalized nutritional/lifestyle recommendation for the public.

Detailed description: Aging is a major risk factor for most fatal diseases, such as Alzheimer's disease, type 2 diabetes, cardiovascular disease, and cancer. Global population aging is becoming increasingly serious, and this trend is mainly driving the annual increase in the prevalence of aging-related diseases. Healthy longevity is influenced by a variety of factors, such as diet structure, lifestyle, ecological environment, gut microbiome, and genetics. At present, research on healthy longevity is mainly focused on Drosophila, nematodes, and mouse models, but few studies have targeted longevity populations. Centenarians and nonagenarians are the best populations to study healthy longevity. However, the multi-omics molecular characteristics and regulatory mechanisms of healthy longevity in humans are still unclear. Therefore, the We-Longevity design includes centenarians, nonagenarians, and senior citizens. We will determine the fecal/serum metabolome, culturable gut microbiome characteristics, gut microbiome, serum proteome, and genome, together with diet, lifestyle, and disease information.

Eligibility criteria: Inclusion Criteria:

* Participants live in Lishui, China.
* Participants intend to remain in Lishui for ≥3 years.

Exclusion Criteria:

* Participants with infectious diseases.

Primary outcomes:
measure: Physical frailty
timeFrame: 36 months
measure: Gut microbiome
timeFrame: 36 months
Secondary outcomes:
measure: Cognitive function
timeFrame: 36 months
measure: Blood biochemical parameters
timeFrame: 36 months
measure: Metabolomics profiling
timeFrame: 36 months
Other outcomes:
Locations:
city: Lishui
country: China
facility: Lishui Yikang Hospital
state: Zhejiang
Study officials:
affiliation: Westlake University
name: Ju-Sheng Zheng, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06024551: Investigation of the Efficacy of Telerehabilitation in Patients With Rotator Cuff Tendinopathy
Official title: Investigation of the Efficacy of Telerehabilitation in Patients With Rotator Cuff Tendinopathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Rotator Cuff Injuries
Rotator Cuff Tendinitis
Keywords: rotator cuff tendinopathy
telerehabilitation
Lead sponsor: Izmir Democracy University
Sponsor class: OTHER
First posted: 2023-09-06
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to investigate the effect of telerehabilitation in patients with rotator cuff tendinopathy. The main questions it aims to answer are:

* Is telerehabilitation effective in improving the functional status of patients with rotator cuff tendinopathy?
* Is telerehabilitation effective in reducing the pain of rotator cuff patients?

Detailed description: Patients between the ages of 18-65 who were diagnosed with rotator cuff tendinopathy will be included in the study. Patients will be divided into two groups. Patients in group 1 will be given a home exercise program. Then, the patients will be called 3 times a week and it will be evaluated whether they do their exercises regularly and whether they do it correctly. At the end of the first month, the patients will be evaluated again for functionality and pain.

The patients in group 2 will be given a home exercise program and at the end of the first month, the patients will be evaluated again in terms of functionality and pain.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Rotator cuff tendinopathy
* Being able to do the prescribed exercises
* Having an access to internet and having a computer or smart phone for telerehabilitation

Exclusion Criteria:

* Patients with a neurological disease that may affect the effectiveness of exercise
* History of fracture in shoulder region
* History of surgery in shoulder region
* Patients with a psychiatric disorder

Primary outcomes:
measure: Western Ontario Rotator Cuff Index
timeFrame: one month
measure: Simple Shoulder Test
timeFrame: one month
Secondary outcomes:
measure: Range of motion
timeFrame: one month
Other outcomes:
Locations:
city: İzmir
country: Turkey
facility: Izmir Democracy University
Study officials:
affiliation: Izmir Democracy University
name: Ferruh Taşpınar
role: STUDY_DIRECTOR
References: